Pharmaceuticalisation as the tobacco industry’s endgame

Yogi Hale Hendlin,Elieen Le Han,Pamela M. Ling

DOI: https://doi.org/10.1136/bmjgh-2023-013866

IF: 8.056

2024-02-01

BMJ Global Health

Abstract:Context Declining smoking prevalence and denormalisation of tobacco in developed countries reduced transnational tobacco company (TTC) profit during 1990s and 2000s. As these companies faced increasingly restrictive policies and lawsuits, they planned to shift their business to socially acceptable reduced-harm products. We describe the internal motivations and strategies to achieve this goal. Methods We analysed previously secret tobacco industry documents available through the Truth Tobacco Documents Library. These documents were triangulated with TTCs’ investor and other professional reports, websites and public statements. Findings Mimicking pharmaceutical business models, tobacco companies sought to refurbish their image and ensure long-term profitability by creating and selling pharmaceutical-like products as smoking declined. These products included snus, heated tobacco products, e-cigarettes, nicotine gums and inhalers. Tobacco companies created separate divisions to develop and roll out these products, and the majority developed medical research programmes to steer these products through regulatory agencies, seeking certification as reduced-harm or pharmaceutical products. These products were regarded as key to the survival of the tobacco industry in an unfriendly political and social climate. Conclusions Pharmaceuticalisation was pursued to perpetuate the profitability of tobacco and nicotine for tobacco companies, not as a sincere search to mitigate the harms of smoking in society. Promotion of new pharmaceuticalised products has split the tobacco control community, with some public health professionals and institutions advocating for the use of ‘clean’ reduced-harm nicotine and tobacco products, essentially carrying out tobacco industry objectives.

public, environmental & occupational health

What problem does this paper attempt to address?

The paper explores how Transnational Tobacco Companies (TTCs) are responding to increasingly stringent tobacco control measures by transforming their products into pharmaceutical-like products (i.e., "pharmaceuticalization") to ensure their long-term profitability. The authors analyze previously confidential tobacco industry documents, TTCs' investment reports, websites, and other public statements.

The paper points out that the decline in smoking rates and the reduced social acceptance of tobacco products in developed countries led to decreased profits for TTCs during the 1990s and 2000s. To adapt to these changes, TTCs planned to shift their business towards products considered less harmful and socially acceptable, such as snus, heated tobacco products, e-cigarettes, nicotine gums, and inhalers. These products are designed in pharmaceutical-like forms to gain regulatory approval, thereby being marketed as less harmful or pharmaceutical products.

TTCs created specialized departments to develop these products and conducted medical research projects to navigate the regulatory approval process. The paper argues that this transformation by TTCs is not genuinely aimed at reducing the harm caused by smoking in society but rather at maintaining the profitability of tobacco and nicotine products. The newly introduced pharmaceuticalized products have already caused divisions within the tobacco control community, with some public health professionals and institutions supporting the use of so-called "clean" low-harm nicotine and tobacco products, effectively achieving TTCs' goals.

Furthermore, the paper discusses how TTCs are reshaping their image by mimicking the pharmaceutical model and how these strategies influence public health policy-making. TTCs attempt to rebrand themselves in the public eye by promoting these new products and seeking collaboration with governments, which violates Article 5.3 of the World Health Organization Framework Convention on Tobacco Control that prohibits tobacco industry involvement in policy-making.

In conclusion, the paper reveals TTCs' strategy to maintain their market position and profits by pharmaceuticalizing their products and highlights the potential negative impact of this strategy on public health.